AR081649A1 - Compuestos heteroarilo nitrogenados - Google Patents
Compuestos heteroarilo nitrogenadosInfo
- Publication number
- AR081649A1 AR081649A1 ARP110101963A ARP110101963A AR081649A1 AR 081649 A1 AR081649 A1 AR 081649A1 AR P110101963 A ARP110101963 A AR P110101963A AR P110101963 A ARP110101963 A AR P110101963A AR 081649 A1 AR081649 A1 AR 081649A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- alkoxy
- optionally substituted
- group
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Dichos compuestos inhiben la PDE10A y pueden utilizarse como medicamentos. Procedimientos de preparación, composiciones farmacéuticas y usos.Reivindicación 1: Un compuesto de fórmula (1) en la que: A1 se selecciona de entre el grupo que consiste de CH y N; A2 se selecciona de entre el grupo que consiste de CR19 y N, con la condición de que A1 y A2 no sean N simultáneamente; el resto de fórmula (a) es arilo o heteroarilo, en el que dicho arilo y dicho heteroarilo se sustituyen opcionalmente con 1 a 3 sustituyentes seleccionados independientemente de entre el grupo que consiste de alquilo inferior, alcoxi inferior, hidroxialquilo inferior, haloalquilo inferior, alcoxi inferior-alquilo inferior, alquilo inferior-C(O)-, -C(O)-N(R8)2, -N(R8)-C(O)-alquilo inferior, ciano, halógeno, R9 y amino, y en el que dicho alquilo inferior se sustituye opcionalmente con oxo, -C(O)OH, alcoxi inferior-C(O)- o R7, y en el que dicho alcoxi inferior se sustituye opcionalmente con hidroxilo, alcoxi inferior o -C(O)-N(R8)2, y en el que dicho amino se sustituye opcionalmente con 1 ó 2 sustituyentes seleccionados independientemente de entre el grupo que consiste de alquilo inferior, hidroxialquilo inferior, alcoxi inferior-alquilo inferior y alquilo inferior-C(O)-; R1 es alquilo inferior, alcoxi inferior, hidroxialquilo inferior, haloalquilo inferior, alcoxi inferior-alquilo inferior, alquilo inferior-C(O)-, -O-haloalquilo inferior, ciano, halógeno, R7 o amino, en los que dicho alquilo inferior se sustituye opcionalmente con R7, y en el que dicho amino se sustituye opcionalmente con 1 ó 2 sustituyentes seleccionados independientemente de entre el grupo que consiste de alquilo inferior y alcoxi inferior-alquilo inferior; R2 y R3 son independientemente hidrógeno o alquilo inferior; R4 es arilo o heteroarilo, en el que dicho arilo y dicho heteroarilo se sustituyen opcionalmente con 1 a 3 sustituyentes seleccionados independientemente de entre el grupo que consiste de hidroxilo, halógeno, alquilo inferior, alcoxi inferior, hidroxialquilo inferior, haloalquilo inferior, alcoxi inferior-alquilo inferior, alquilo inferior-C(O)-, ciano y amino, en los que dicho amino se sustituye opcionalmente con 1 ó 2 sustituyentes seleccionados independientemente de entre el grupo que consiste de alquilo inferior y alcoxi inferior-alquilo inferior; R5 y R6 son independientemente hidrógeno, alquilo inferior, alcoxi inferior, haloalquilo inferior, cianoalquilo inferior, hidroxialquilo inferior, alcoxi inferior-alquilo inferior, cicloalquilo o heterociclilo, en los que dicho alquilo inferior se sustituye opcionalmente con oxo, R7 o -N(R8)2, y en los que dicho haloalquilo inferior se sustituye opcionalmente con hidroxilo, y en el que dicho cicloalquilo y dicho heterociclilo se sustituyen opcionalmente con 1 a 3 sustituyentes seleccionados independientemente de entre el grupo que consiste de hidroxilo, halógeno, alquilo inferior, alcoxi inferior, hidroxialquilo inferior, haloalquilo inferior, alcoxi inferior-alquilo inferior, acetilo, ciano, -C(O)-alcoxi inferior y N(R8)2, o R5 y R6, conjuntamente con el átomo de nitrógeno al que se encuentran unidos, forman un heterociclilo o espiro-heterociclilo, en el que dicho heterociclilo y dicho espiro-heterociclilo se sustituyen opcionalmente con 1 a 3 sustituyentes seleccionados independientemente de entre el grupo que consiste de hidroxilo, halógeno, alquilo inferior, alcoxi inferior, hidroxialquilo inferior, haloalquilo inferior, alcoxi-inferior-alquilo inferior, alquilo inferior-C(O)-, ciano, oxo y amino, y en el que dicho amino se sustituye opcionalmente con 1 ó 2 sustituyentes seleccionados independientemente de entre el grupo que consiste de alquilo inferior, hidroxialquilo inferior y alcoxi inferior-alquilo inferior; R7 es cicloalquilo o heterociclilo, en el que dicho cicloalquilo y dicho heterociclilo se sustituyen opcionalmente con 1 ó 2 sustituyentes seleccionados independientemente de entre el grupo que consiste de alquilo inferior, hidroxialquilo inferior, alcoxi inferior-alquilo inferior, halógeno y haloalquilo inferior; R8 se selecciona independientemente de entre el grupo que consiste de hidrógeno, alquilo inferior, hidroxialquilo inferior y alcoxi inferior-alquilo inferior; R9 es cicloalquilo, heterociclilo, arilo o heteroarilo, en los que dicho cicloalquilo, dicho heterociclilo, dicho arilo y dicho heteroarilo se sustituyen opcionalmente con 1 ó 2 sustituyentes seleccionados independientemente de entre el grupo que consiste de alquilo inferior, hidroxialquilo inferior, alcoxi inferior-alquilo inferior, halógeno y haloalquilo inferior; R19 es hidrógeno o tetrahidrofuran-2-ilo; o una sal farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10165427 | 2010-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR081649A1 true AR081649A1 (es) | 2012-10-10 |
Family
ID=44483879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110101963A AR081649A1 (es) | 2010-06-09 | 2011-06-07 | Compuestos heteroarilo nitrogenados |
Country Status (24)
Country | Link |
---|---|
US (1) | US8703768B2 (es) |
EP (1) | EP2580207B1 (es) |
JP (1) | JP5940523B2 (es) |
KR (1) | KR101757959B1 (es) |
CN (1) | CN102947292B (es) |
AR (1) | AR081649A1 (es) |
BR (1) | BR112012031343A2 (es) |
CA (1) | CA2799022A1 (es) |
CL (1) | CL2012003421A1 (es) |
CO (1) | CO6620065A2 (es) |
CR (1) | CR20120594A (es) |
EA (1) | EA022075B1 (es) |
EC (1) | ECSP12012330A (es) |
HK (1) | HK1178900A1 (es) |
IL (1) | IL223069A0 (es) |
MA (1) | MA34340B1 (es) |
MX (1) | MX2012013907A (es) |
NZ (1) | NZ603230A (es) |
PE (1) | PE20130279A1 (es) |
SG (1) | SG185655A1 (es) |
TW (1) | TW201202221A (es) |
UA (1) | UA108105C2 (es) |
WO (1) | WO2011154327A1 (es) |
ZA (1) | ZA201209119B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102164896A (zh) * | 2008-10-14 | 2011-08-24 | 埃科特莱茵药品有限公司 | 苯乙基酰胺衍生物及其杂环类似物 |
EA201290957A1 (ru) | 2010-04-07 | 2013-04-30 | Ф.Хоффманн-Ля Рош Аг | Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения |
MX2013009575A (es) | 2011-02-18 | 2014-10-14 | Exonhit Therapeutics Sa | Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a). |
KR20140074964A (ko) | 2011-09-27 | 2014-06-18 | 에프. 호프만-라 로슈 아게 | 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법 |
EP2712862A1 (en) * | 2012-09-28 | 2014-04-02 | Splicos | New anti-invasive compounds |
EP2903613B1 (en) * | 2012-10-08 | 2017-11-22 | Merck Sharp & Dohme Corp. | Pyrazole derivatives useful as inhibitors of irak4 activity |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
CN106957317B (zh) | 2013-02-27 | 2019-12-31 | 持田制药株式会社 | 新型吡唑衍生物 |
ES2624453T3 (es) * | 2013-04-29 | 2017-07-14 | F. Hoffmann-La Roche Ag | Derivados de 2-fenil o 2-hetaril-imidazol[1,2-a]piridina |
GB201316600D0 (en) * | 2013-09-18 | 2013-10-30 | Redx Pharma Ltd | Agricultural chemicals |
US20160264536A1 (en) * | 2013-10-23 | 2016-09-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
US10420341B2 (en) * | 2015-01-30 | 2019-09-24 | Basf Se | Herbicidal phenylpyrimidines |
WO2016127024A1 (en) * | 2015-02-06 | 2016-08-11 | Merck Patent Gmbh | Pyridazinone macrocycles as irak inhibitors and uses thereof |
CN104610189A (zh) * | 2015-02-10 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一类含环丙基脒结构sglt2/sglt1双靶点抑制剂及用途 |
CN104974075A (zh) * | 2015-08-07 | 2015-10-14 | 新秀化学(烟台)有限公司 | 一种n, n-二(2,2,6,6-四甲基-4-哌啶基) -1,3-苯二甲酰胺的制备方法 |
WO2018013597A1 (en) * | 2016-07-12 | 2018-01-18 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
EA201990347A1 (ru) | 2016-07-26 | 2019-08-30 | Басф Се | Гербицидные пиримидиновые соединения |
CN109475127A (zh) | 2016-07-27 | 2019-03-15 | 巴斯夫欧洲公司 | 除草的嘧啶化合物 |
WO2018019767A1 (en) | 2016-07-27 | 2018-02-01 | Basf Se | Herbicidal pyridine compounds |
EP3490380A1 (en) | 2016-07-28 | 2019-06-05 | Basf Se | Herbicidal pyrimidine compounds |
WO2018136264A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
AR110740A1 (es) | 2017-01-23 | 2019-05-02 | Revolution Medicines Inc | Compuestos bicíclicos como inhibidores alostéricos de shp2 |
JP2020536881A (ja) | 2017-10-12 | 2020-12-17 | レヴォリューション・メディスンズ,インコーポレイテッド | アロステリックshp2阻害剤としてのピリジン、ピラジンおよびトリアジン化合物 |
SG11202004090YA (en) | 2017-12-15 | 2020-05-28 | Revolution Medicines Inc | Polycyclic compounds as allosteric shp2 inhibitors |
WO2019121374A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Herbicidal pyrimidine compounds |
WO2019121352A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Herbicidal pyrimidine compounds |
AU2018389763B2 (en) * | 2017-12-20 | 2023-02-23 | Pi Industries Ltd. | Pyrazolopyridine-diamides, their use as insecticide and processes for preparing the same. |
PL3853219T3 (pl) | 2018-09-19 | 2023-12-18 | Bayer Aktiengesellschaft | Herbicydowo działające podstawione fenylopirymidynohydrazydy |
SG11202104326TA (en) * | 2018-11-02 | 2021-05-28 | Merck Sharp & Dohme | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
EP4052760B1 (en) | 2019-10-31 | 2024-03-13 | FUJIFILM Corporation | Pyrazine derivative or salt thereof, and use of same |
JPWO2022025174A1 (es) | 2020-07-30 | 2022-02-03 | ||
MX2023005550A (es) | 2020-11-13 | 2023-07-18 | Inipharm Inc | Inhibidores de diclorofenol hsd17b13 y usos de los mismos. |
EP4319872A1 (en) * | 2021-04-05 | 2024-02-14 | Inipharm, Inc. | Thiazole/isothiazole hsd17b13 inhibitors and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
EP1193261A1 (en) | 2000-10-02 | 2002-04-03 | Warner-Lambert Company | New thiadiazoles and their use as phosphodiesterase-7 inhibitors |
US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
JP2007524682A (ja) | 2004-02-12 | 2007-08-30 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−5の調節物質としてのビピリジルアミド |
CN101133027B (zh) * | 2005-03-04 | 2011-03-30 | 弗·哈夫曼-拉罗切有限公司 | 作为mglur5拮抗剂的吡啶-2-甲酰胺衍生物 |
US20060199828A1 (en) | 2005-03-04 | 2006-09-07 | Georg Jaeschke | Pyrazine-2-carboxyamide derivatives |
AR057987A1 (es) | 2005-11-24 | 2008-01-09 | Astrazeneca Ab | Compuestos agonistas de cb1 (receptor cannabinoide) |
CA2679659C (en) | 2007-03-01 | 2016-01-19 | Novartis Ag | Pim kinase inhibitors and methods of their use |
WO2009026241A1 (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 |
US8470820B2 (en) | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
-
2011
- 2011-06-02 US US13/151,301 patent/US8703768B2/en active Active
- 2011-06-06 EA EA201291282A patent/EA022075B1/ru not_active IP Right Cessation
- 2011-06-06 KR KR1020137000568A patent/KR101757959B1/ko active IP Right Grant
- 2011-06-06 BR BR112012031343A patent/BR112012031343A2/pt not_active Application Discontinuation
- 2011-06-06 CN CN201180027950.8A patent/CN102947292B/zh not_active Expired - Fee Related
- 2011-06-06 WO PCT/EP2011/059234 patent/WO2011154327A1/en active Application Filing
- 2011-06-06 MX MX2012013907A patent/MX2012013907A/es active IP Right Grant
- 2011-06-06 UA UAA201214955A patent/UA108105C2/ru unknown
- 2011-06-06 MA MA35502A patent/MA34340B1/fr unknown
- 2011-06-06 SG SG2012085015A patent/SG185655A1/en unknown
- 2011-06-06 CA CA2799022A patent/CA2799022A1/en not_active Abandoned
- 2011-06-06 JP JP2013513638A patent/JP5940523B2/ja not_active Expired - Fee Related
- 2011-06-06 EP EP11723077.1A patent/EP2580207B1/en not_active Not-in-force
- 2011-06-06 PE PE2012002298A patent/PE20130279A1/es not_active Application Discontinuation
- 2011-06-06 NZ NZ603230A patent/NZ603230A/xx not_active IP Right Cessation
- 2011-06-07 AR ARP110101963A patent/AR081649A1/es unknown
- 2011-06-08 TW TW100120008A patent/TW201202221A/zh unknown
-
2012
- 2012-10-26 CO CO12192367A patent/CO6620065A2/es active IP Right Grant
- 2012-11-15 IL IL223069A patent/IL223069A0/en unknown
- 2012-11-26 CR CR20120594A patent/CR20120594A/es unknown
- 2012-12-03 ZA ZA2012/09119A patent/ZA201209119B/en unknown
- 2012-12-05 CL CL2012003421A patent/CL2012003421A1/es unknown
- 2012-12-07 EC ECSP12012330 patent/ECSP12012330A/es unknown
-
2013
- 2013-05-17 HK HK13105859.4A patent/HK1178900A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1178900A1 (en) | 2013-09-19 |
CO6620065A2 (es) | 2013-02-15 |
IL223069A0 (en) | 2013-02-03 |
ECSP12012330A (es) | 2012-12-28 |
CL2012003421A1 (es) | 2013-07-26 |
MA34340B1 (fr) | 2013-06-01 |
JP2013528193A (ja) | 2013-07-08 |
KR20130112858A (ko) | 2013-10-14 |
JP5940523B2 (ja) | 2016-06-29 |
US20110306589A1 (en) | 2011-12-15 |
EA022075B1 (ru) | 2015-10-30 |
EP2580207A1 (en) | 2013-04-17 |
CA2799022A1 (en) | 2011-12-15 |
NZ603230A (en) | 2013-09-27 |
CN102947292A (zh) | 2013-02-27 |
PE20130279A1 (es) | 2013-03-08 |
UA108105C2 (ru) | 2015-03-25 |
EA201291282A1 (ru) | 2013-06-28 |
US8703768B2 (en) | 2014-04-22 |
CR20120594A (es) | 2013-01-03 |
CN102947292B (zh) | 2015-08-19 |
BR112012031343A2 (pt) | 2016-11-01 |
EP2580207B1 (en) | 2017-09-27 |
MX2012013907A (es) | 2012-12-17 |
ZA201209119B (en) | 2015-05-27 |
WO2011154327A1 (en) | 2011-12-15 |
TW201202221A (en) | 2012-01-16 |
KR101757959B1 (ko) | 2017-07-14 |
SG185655A1 (en) | 2012-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR081649A1 (es) | Compuestos heteroarilo nitrogenados | |
AR083070A1 (es) | Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc | |
AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
AR087184A1 (es) | Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienen | |
AR082004A1 (es) | Compuestos de fusion de piridina | |
AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
CO6020016A1 (es) | Derivados de 1,2,4,5 tetrahidro-3h-benzapezinas su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
ECSP12012292A (es) | Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos | |
AR069435A1 (es) | Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa | |
CO6440533A2 (es) | Nucleósidos espiro oxetánicos uracílicos | |
AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
AR049346A1 (es) | 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas | |
AR084152A1 (es) | Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc | |
CO6160307A2 (es) | Compuestos de pirazolina y su uso y composiciones farmaceuticas | |
AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
AR067574A1 (es) | Derivados de piperazin-2-ona | |
CO5700768A2 (es) | Derivados de benzoxazina y sus usos | |
AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 | |
AR055297A1 (es) | Ligandos moduladores de los receptores rars, utilizacion en medicina humana asi como en cosmetica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |